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1. Introduction
The field of epigenetics describes information transmission through cell divisions of heritable
changes of gene transcription activity without DNA sequence changes. Epigenetic informa‐
tion is biologically important for tissue or organ development and cell differentiation. Altera‐
tion of epigenetic information is involved in the development of cancers and other diseases.
DNA methylation, histone modifications, and transmitted chromatin structure are the under‐
lying mechanisms for epigenetic transmission. Aberrant DNA methylation is found in two dis‐
tinct forms, hypermethylation and hypomethylation. Global hypomethylation and regional
hypermethylation are characterized as two features of human cancer cells [1,2].
The regional hypermethylation involves CpG islands located in the promoter and 5’-exon(s).
DNA methylation, the incorporation of a methyl group to the C-5 position of the cytosine
ring in the context of 5’-CpG-3’ dinucleotides, which leads to the formation of 5-methylcyto‐
sine (5-mC), is the most studied epigenetic change to date in gastric carcinogenesis. Hyper‐
methylation of CpG islands recruits methyl DNA binding proteins, and subsequently
histone deacetylases. Deacetylation of the histone tails makes the DNA structure of the pro‐
moter into a closed chromatin structure that is inaccessible to transcription factors leading to
transcriptional silencing of tumor suppressor genes, mimicking their genetic mutations.
Thus, aberrant hypermethylation of these CpG islands acts as an alternative way to genetic
changes for the inactivation of tumor suppressor genes. Global hypomethylation at repeti‐
tive sequences causes genomic instability. Both types of DNA methylation changes were im‐
plicated in the development and progression of cancers [1-3].
It is interesting to note that site-specific gene hypermethylation is an early event in H. pylori
-related gastric carcinogenesis. Kang et al. [4] indicated that gastric cancer (GC) as well as its
associated normal mucosa exhibited the highest number of methylated genes when com‐
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pared the tissues from other organs, including the lung, breast, colon, and liver (Fig. 1). This
suggests the possibility that aberrant hypermethylation of CpG islands is more involved in
the carcinogenesis in the stomach than in the other human tissues or organs. Methylation
changes of some CpG islands can be detected in cancer tissues and morphologically normal
gastric tissues from patients with GC or precancerous lesions, including epithelium dyspla‐
sia and intestinal metaplasia, but cannot be observed in gastritis lesions or normal gastric
tissues from subjects without malignant disease.
Figure 1. Bar graphs display the number of methylated genes in cancer-associated normal tissues (A) and cancer tis‐
sues (B). [4] The error bars indicate the standard error of the mean. Forty-one genes are analyzed for their methylation
status in tissue samples from eight human cancer tissue types and six types of cancer-associated normal tissue using
the MethyLight assay. EHC, extrahepatic bile duct cancer; PrC, prostate adenocarcinoma; BrC, breast adenocarcinoma;
CRC, colorectal adenocarcinoma; EsC, esophageal adenocarcinoma; HCC, hepatocellular carcinoma; LuC, lung adeno‐
carcinoma; GC, gastric adenocarcinoma.
2. Accumulation of DNA methylation changes in progressions of
gastritis, intestinal metaplasia, and dysplasia to GC
As early as in the 19th century, a German pathologist von Waldeyer stated that ‘cancer, in
particular gastric cancer, may be considered an adaptive response to an adverse environ‐
ment, characterized by a progressive phenotypic alteration.’ Currently, it is well accepted
that the phenotypic transformation preceding GC, that is, superficial gastritis, chronic atro‐
phic gastritis (CAG), intestinal metaplasia, and dysplasia/adenoma, are the consequences of
an accumulation of molecular alterations triggered by a chronic inflammatory process [5,6].
Therefore, the progressive phenotypic alteration could at times represent an altered epige‐
nome, which is the result of host adaptive responses to environmental exposure. If hyper‐
methylation of promoter CpG islands of some genes plays an important role in the
malignant transformation of gastric epithelial cells, it’s reasonable to assume that the pattern
of hypermethylation could be found in premalignant lesions in the stomach. Kang et al. in‐
vestigated the methylation profile in multistep lesions of the stomach and determined the
methylation frequency of 12 genes, including APC, COX-2,DAP-kinase, E-cadherin, GSTP1,
hMLH1, MGMT, p16, p14, RASSF1A, THBS1, and TIMP3, by methylation-specific PCR.They
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demonstrated that hypermethylation of certain promoter CpG islands occurs early in gastric
carcinogenesis and accumulates during progression of the gastric lesion along the multistep
carcinogenesis [7-9]. Tables 1 lists the methylation frequencies of tested CpG islands. The
most tested CpG islands exhibited increase methylation tendency along the progression,
such as COX-2, DAP-kinase, GSTP1, hMLH1, p14, p16, RASSF1A, THBS1, and TIMP-3. The
average number of methylated genes was 2.7, 3.6, 3.4, and 5.2 per 12 tested genes in CG, IM,
GA, and GC, respectively. Methylation index was defined as ratio of the number of methy‐
lated genes to the number of total tested genes. The average methylation index was 0.23, 0.3,
0.28, and 0.43 in chronic gastritis, intestinal metaplasia, adenoma, and cancer, respectively.
The methylation index was significantly higher for precancerous lesions intestinal metapla‐
sia and adenoma than for gastritis. A significant increase of methylation frequency was ob‐
served from these pre-malignant lesions to gastric cancer [8].
CG(N=74) (%) IM(N=57) (%) GA(N=79) (%) GC(N=80) (%) p value
APC 48 (64.9) 46 (80.7) 57 (72.2) 62 (77.5) NSa
COX2 1 (2.2) 5 (8.8) 3 (3.8) 37 (46.3) < 0.001
DAP-K 26 (35.1) 28 (49.1) 27 (34.2) 45 (56.3) 0.012
E-cadherin 63 (85.1) 41 (71.9) 46 (58.2) 53 (67.5) 0.003
GSTP1 0 0 0 13 (16.3) < 0.001
hMLH1 0 4 (7) 7 (8.9) 16 (20) < 0.001
MGMT 11 (14.9) 5 (8.8) 8 (10.1) 17 (21.3) NS
p14 22 (29.7) 18 (31.6) 60 (75.9) 50 (62.5) < 0.001
p16 2 (2.7) 4 (7) 9 (11.4) 35 (43.8) < 0.001
RASSF1A 0 0 0 6(7.5) 0.001
THBS1 13 (17.6) 28 (49.1) 27 (34.2) 45 (56.3) < 0.001
TIMP3 17 (23) 25 (43.9) 22 (27.8) 52 (65) < 0.001
Average number of
methylated genes
2.7b 3.6c,d 3.4b,c 5.2d
methylation index 0.23 0.3 0.28 0.43
aNot significant (p>0.05).
b Chronic gastritis versus gastric adenoma; p = 0.034; Student’s t test.
c Intestinal metaplasia versus gastric adenoma; p = 0.527; Student’s t test.
d Intestinal metaplasia versus gastric carcinoma; p <0.001; Student’s t test.
Table 1. Methylation Frequency of Each Gene in CG, IM, GA, and GC [8]
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During multistep gastric carcinogenesis, there is a steep rise in the number of methylated
genes from chronic gastritis to intestinal metaplasia, which was a consistent finding in a ser‐
ies of studies. Intestinal metaplasia is a precancerous lesion with the typical characteristics
of trans-differentiation of gastric progenitor cells into those committed to intestinal cell line‐
age, which normally present in intestinal mucosa [10]. Regardless of the status of H. pylori
infection, the number of methylated genes in chronic gastritis with intestinal metaplasia was
significantly higher than that in chronic gastritis without intestinal metaplasia[9]. This sug‐
gests that intestinal metaplasia is an epigenetically altered lesion. Hypermethylation of pro‐
moter CpG island in chronic gastritis without intestinal metaplasia occurs in association
with H. pylori infection [11] and aging [12,13]. It is unknown whether trans-differentiation
results in these epigenetic changes.
Although the loss of DNA methylation was the first epigenetic alteration identified in can‐
cer[14], global hypomethylation has been overlooked in favor of gene promoter associated
hypermethylation. Global DNA hypomethylation is associated with hypomethylation of
normally methylated repetitive sequences, such as LINE1, Alu, and Satα, as well as centro‐
meres and microsatellite DNA [15, 16]. In a recent study, using the immunohistochemical
evaluation of 5-mC, Compare et al. [6] have found a gradual decrease in the global DNA
methylation from H. pylori-negative normal gastric biopsy to H. pylori-positive chronic gas‐
tritis lesions, H. pylori-positive CAG, and GC tissues, which suggests that the global DNA
hypomethylation could be implicated in H. pylori-related gastric carcinogenesis at an early
stage. H. pylori-eradication can not reverse the global hypomethylation in precancerous le‐
sions. This has been confirmed by assessing hypomethylation of repetitive sequences in‐
stead of by the global 5-methylcytosine content. Yoshida et al. [17] have reported increased
hypomethylation of DNA repetitive elements through the multistep process of gastric carci‐
nogenesis and suggested that H. pylori infection may induce hypomethylation of repetitive
elements. Although the exact mechanism by which the global loss of DNA methylation con‐
tributes to the neoplastic process is unknown, it is believed that it may induce chromosomal
instability and activate cellular proto-oncogenes, which leading to an increased risk of can‐
cer. Bester et al. have reported that nucleotide deficiency promotes genomic instability in
early stages of cancer development [18]. It is interesting to investigate if the nucleotide defi‐
ciency also leads to the global hypomethylation.
Indeed, hypomethylation and hypermethylation of CpG islands in the gene promoter region
may activate proto-oncogenes or inactivate tumour suppressor genes that confer selective
growth advantage leading ultimately to cell hyperproliferation and cancerous growth
[19,20].
3. Dynamic DNA methylation related to progression of gastritis
The stomach is one of the organs frequently showing aberrant methylation of CpG islands in
epithelial cells because it is directly contacted with chemical and biological toxic agents dai‐
ly. DNA methylation changes accumulate continuously during progression of gastritis, par‐
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ticularly during the establishment of the methylation pattern. Dynamic changes of
methylation pattern occur consistently for gastric mucosae cells adapting to the environ‐
mental causal factors such as H. pylori infection, high concentration of salts, and N-nitroso
compounds. For example, on one hand, p16 inactivation by methylation in cancer cells is
very stable. Methylation of p16 CpG islands can be gradually restored within about two
weeks after demethylation induced by DNMT1 inhibitor treatment [21]. On the other hand,
p16 methylation in gastric tissues can be reversed after H. pylori eradication, which will dis‐
cuss below. This fluctuation nature can be partially explained by the dynamic induction of
methylation/demethylation.
3.1. Association between methylation of CpG islands and environmental/dietary factors,
lifestyle, aging in gastric carcinogenesis
Despite strong evidences from observational epidemiology data and experimental animal
studies suggesting that environmental/dietary factors, lifestyle, and aging are risk factors of
gastric cancer, there has been limited understanding of the mechanisms through which such
exposures have their effects on the molecular steps in tumorigenesis. It is now becoming appa‐
rent that altered epigenetic marks may play a fundamental role in determining not only sus‐
ceptibility to cancer, but also contribute to promote neoplastic pathogenesis. Alternatively, the
altered epigenome could at times represent adaptive responses to environmental exposure.
Environmental factors known to play crucial roles in the etiology of human cancer include
chemical carcinogens (such as those found in cigarette smoke), microorganism infections, di‐
etary contaminants (such as N-nitroso compounds), and lifestyles (such as alcohol consump‐
tion, excess intake of salt), deficiency of nutritional regimes. Stress may also contribute to
the development of gastric cancer. Environmental and dietary factors in animals and hu‐
mans inevitably affect epigenetic patterns, although a clear-cut causal relationship has yet to
be established. The major obstacle in establishing such relationship is the fact that environ‐
mental and dietary factors induce changes are most likely subtle and cumulative, and culmi‐
nate into a quantitative manifestation over a long period of time.
While animal and human studies have linked dietary factors to epigenetic regulation, it has
been challenging to determine the exact mechanisms that nutrients may systemically affect
epigenetic changes. The most studied and best-understood fact is the relationship between
dietary methyl donors (including vitamins B6 and B12, methionine, and folate) and DNA
methylation [22]. As an essential amino acid, methionine plays the central role in the epige‐
netic regulation by serving as a methyl donor for methylation reactions. In the process of cy‐
tosine methylation, DNMT enzyme converts the donor S-adenosyl-L-methionine (SAM) to
S-adenosylhomocysteine (SAH), and transfers a methyl group from the donor SAM to the
C-5 cytosine carbon atom. Therefore, an optimal supply of SAM or removal of SAH is essen‐
tial for a normal establishment of genome-wide DNA methylation patterns. When methyl
groups are in short supply, there is a competition for the limited resources. Perturbations in
this system may be caused by dietary imbalances affecting the supply of methyl donors such
as folate.
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Because humans tend to consume foods and nutrients that are highly interrelated, study of
dietary patterns may have improved the power of detecting the effect of diet on DNA meth‐
ylation. In humans, studies on diet and DNA methylation have yielded inconsistent find‐
ings.Animal studies have provided direct evidence that dietary factors induce changes in
DNA methylation patterns. Bai et al. investigated whether p16 hypermethylation is an early
and frequent event in gastric carcinogenesis induced by N-methyl-N’-nitro-N-nitrosoguani‐
dine (MNNG).The frequency and timing of p16 hypermethylation during the multistep gas‐
tric carcinogenesis in Wistar rats were analyzed in various microdissected gastric lesions.
Our group has found that p16 methylation is a frequent and early event during MNNG-in‐
duced gastric carcinogenesis of rats [23]. The frequency of p16 methylation is positively cor‐
related with the severity of pathological abnormality of mucosa and negatively correlated
with the expression of P16. The p16 methylation in the distal glandular stomach epithelium
was higher than that in the proximal stomach. These results suggest that hypermethylation
of CpG islands may account for the silencing of p16 in rat stomach and is an early event
whose accumulation will finally lead to gastric carcinogenesis [23].(Table 2)
Pathological status Proximal Distal Total
Normal 0/16(0) 1/20(5.0) 1/36(2.8)
Chronic atrophic gastritis 3/20(15.0) 1/4(25.0) 4/24(16.7)
Dysplasia 3/13(23.1) 6/11(54.5) 9/24(37.5)a
Adenoma II 4/6(66.7) 11/17(64.7) 15/23(65.0)a
Adenoma I 4/6(66.7) 10/14(71.4) 14/20(70.0)a,b
Adenocarcinoma 5/5(100) 18/22(81.8) 23/27(85.2)a,b,c
Total 19/66(28.8) 47/88(53.4)d
aNormal vs. dysplasia, adenoma-I/II, and adenocarcinoma, P<0.001.
bChronic atrophic gastritis vs. adenoma-I and adenocarcinoma, P<0.001.
cDysplasia vs. adenocarcinoma, P<0.002.
dProximal vs. distal, P<0.001.
Table 2. Frequency (%) of p16 methylation in tumors and various precancerous tissues of rat glandular stomach by
MNNG [23]
Promoter methylation is also present in non-neoplastic cells as an age-related tissue-specific
phenomenon. Aging was first revealed to be an methylation inducing factor of ER methyla‐
tion in colonic mucosae [24]. The correlation between high incidence of gastric cancers in
older people and high methylation frequency of CpG islands suggests the link of aging and
cancer via increased methylation changes of CpG islands. Waki et al. [12] found that methyl‐
ation of E-cadherin and p16 was not seen in non-neoplastic cells of organs from people (n=6;
≤22 years old). In contrast, these genes were methylated in non-neoplastic gastric epithelial
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cells of persons (n=14; ≥45 years old) 86% and 29%, respectively. Considering that non-neo‐
plastic gastric mucosae from GC patients harbor higher methylation levels of CpG islands
than gastric mucosae from control patients without GC, these non-cancer subjects with high
methylation levels of CpG islands are expected to be at increased risk of GC. The finding
that the stomach is one of the organs with a high frequency of aging-related methylation is
consistent with the finding that GC is one of the tumors with a high frequency of CpG island
methylation. The causes for high frequency of DNA methylation in the stomach may be re‐
lated to the accumulation of the gastric mucosa to exogenous agents or a set of programmed
aging events.
3.2. Induction of aberrant DNA methylation in gastric mucosa by H. pylori infection
Up to 80% of GC patients have a current or past H. pylori infection [25]. World Health Or‐
ganization has designated H. pylori as a human class I carcinogen for gastric malignancy. Al‐
though the exact mechanism of H. pylori-associated gastric carcinogenesis is still elusive,
long-standing bacterial infection, perpetuated chronic inflammation, and sustained mucosal
epithelial cell proliferation are thought to produce a carcinogenic environment which gradu‐
ally causes epigenetic reprogramming of host cells in the stomach. Chan et al. [11] were the
first to demonstrate H. pylori-associated hypermethylation in the gastric epithelia, which
was consist with a recent study established the correlation between H. pylori infection and
high levels of aberrant DNA methylation in gastric cancer. Maekita et al. [26] compared
methylation levels in the non-cancerous gastric mucosae of GC and non-cancer patients with
and without H. pylori infection, respectively. They found that methylation levels of several
CpG islands in H. pylori-positive individuals were 5.4- to 303-fold higher than those in H.
pylori-negative individuals [27]. They also found that, among H. pylori-negative individuals,
methylation levels were 2.2- to 32-fold higher in the non-cancerous gastric mucosae of GC
patients than in the normal gastric mucosa of healthy individuals. (Fig. 2)
The fraction of methylated DNA molecules was quantified for eight regions of seven genes
using DNA from the antral noncancerous gastric mucosae. Methylation levels increased in
individuals with H. pylori infection whether or not they had gastric cancer. When methyla‐
tion levels were compared among individuals without H. pylori infection, they were clearly
higher in gastric cancer patients than in healthy volunteers. Error bars: standard errors
Our group studied the p16 methylation among 920 subjects with gastric lesions and its asso‐
ciation with H. pylori infection. The frequency of p16 methylation was significantly higher in
H. pylori positive subjects than H. pylori negative subjects in each category of gastric lesion.
Compared with H. pylori negative, the odd ratios (ORs) of p16 methylation were markedly
elevated in H. pylori positive subjects for superficial gastritis (OR, 9.45; 95% confidence inter‐
val [CI]: 2.94–30.41), chronic atrophic gastritis (OR, 15.92; 95%CI: 7.60–33.36), intestinal met‐
aplasia (OR, 4.46; 95%CI: 2.44–8.13), indefinite dysplasia (OR, 3.67; 95%CI:,1.90–7.10), and
dysplasia (OR, 2.48; 95%CI: 1.02–5.99).(table 4) Moreover, the frequencies of p16 methylation
increased steadily with the H. pylori density in gastric mucosa [28]. (table 3)
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Figure 2. Methylation levels in the noncancerous gastric mucosae of individuals with and without H. pylori infection,
and with and without gastric cancer[27].
Pathological category H.pylori status Methylation frequency of p16 p value1 OR2(95%CI)
SG No 18.6%（11/59） <0.001 1.00
Yes 68.4%(13/19) 9.45(2.94-30.41)
CAG No 21.5%(14/65) <0.001 1.00
Yes 81.8%(108/132) 15.92(7.60-33.36)
IM No 23.3%(20/86) <0.001 1.00
Yes 57.0%(81/142) 4.46(2.44-8.13)
Ind DYS No 36.7%(18/49) <0.001 1.00
Yes 67.4%(145/215) 3.67(1.90-7.10)
DYS No 24.3%(9/37) <0.001 1.00
Yes 45.5%(35/77) 2.48(1.02-5.99)
1Pearson’s x2 test.-2adjusted for gender, age, smoking and drinking.
Table 3. p16 Methylation Associated With H. Pylori Infection by Paathological Category [28]
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Eradiation of H. pylori infection could not reverse all epigenetic changes in gastric mucosae.
Leung et al. [29] have reported that one year after H. pylori eradication, there is a marked
reduction in the mean methylation density of the CDH1 gene in both the promoter region
and exon-1. Perri et al. [30] have observed partial regression of epigenetic events one year
after successfully eradicating of H. pylori infection therapy. CDH1, p16, and APC methyla‐
tion significantly decrease while COX2 methylation completely disappear. Moreover, an an‐
imal model was adopted to strengthen these findings. H. pylori infection is best modeled in
Mongolian gerbils. The incidence of gastric cancers in gerbils depends on the duration of H.
pylori infection, and eradication of H. pylori significantly reduces the incidence [31]. Thus,
this model is expected to be useful in analyzing detailed molecular mechanisms for induc‐
tion of aberrant DNA methylation.Mongolian gerbils experimentally infected with H. pylori
and subsequent genome-wide screening exhibited hypermethylation at several CpG islands
in the gastric mucosae. Methylation levels started to increase 5-10 weeks after the infection,
reached high levels by 50 weeks. Clearance of the infection resulted in markedly decreased
methylation levels 10 and 20 weeks later, but they remained elevated compared with that in
non-infected animals [32,33]. Thus, it is strongly in support of the potential beneficial effects
of H. pylori eradication on the reversal of promoter hypermethylation in the non-cancerous
stomach and possibly on chemoprevention of GCs. These findings also suggest that some
methylation changes induced by H. pylori infection are temporary and some of them are per‐
sistent which is not dependent on consistent H. pylori infection.
The dynamic and reversible nature of methylation profile could be explained by an old con‐
cept that stem cells may be the cellular origin of cancer. Although it is unknown which
methylation changes in the genome are reversible or not, one of the possible mechanisms for
the diverse fates of methylation of CpG islands is that the fates of methylation is dependent
on the fates of host cells in which the methylation occurs. The aberrant methylations are
likely temporary events if they occur in fully or partially differentiated epithelial cells, be‐
cause most gastric epithelial cells will quickly drop off from the gastric epithelium through
regular regeneration within several days. The methylation changes are likely permanent if
they occur in tissue stem cells, because these cells will remain for life-time in the stomach
and even benefit from these changes. It is reported that the temporary component is the one
that disappears after eradicating the infection [34-36]. Further works have demonstrated the
existence of gene specificity in the DNA hypermethylation induced by infection. Methyla‐
tion of specific genes that occurs in a significant number of cells in the mucosa establishes an
‘epigenetic field for cancerisation’ or ‘epigenetic field defect’, characterizing a site with high
risk for subsequent malignant transformation [33, 37].
Although the mechanistic understanding of the H. pylori-induced alteration of DNA methyl‐
ation is limited, one plausible explanation is mediated by interleukin-1 beta (IL-1β). The lev‐
el of IL-1β in gastric mucosa is up-regulated in specimens infected with both cagA positive
and negative H. pylori strains [38,39]. Furthermore, Hmadcha et al. [40] have found that
IL-1β, through the production of nitric oxide (NO) and the subsequent activation of DNA
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methyltransferase, may induce CpG island methylation. NO is a gaseous free radical which
can be produced intracellularly by nitric oxide synthase (NOS)-mediated oxidation of argi‐
nine or formed in the acidic stomach through the alternative nitrate-dependent NO path‐
way. H. pylori infection has been shown to be associated with up-regulation of inducible
nitric oxide synthase (iNOS) both in vivo and in vitro[41,42]. Increased iNOS activity has
been observed in both patients with chronic gastritis and GC patients [43]. In addition, IL-1β
siRNA blocked H. pylori-induced methylation of the CDH1 promoter CpG island in a gastric
cancer cell line [44]. In an animal experiment by the Ushijima team, it has found that H. pylo‐
ri infection induces hypermethylation of CpG island of candidate genes, and that the eradi‐
cation leads to marked decrease of methylation levels in these genes [32]. Notably, the
suppression of inflammation by treatment of the immunosuppressive drug cyclosporine,
which suppresses inflammation without affecting bacterial colonization, abolishes this aber‐
rant methylation in the candidate genes. These findings suggest that the infection-associated
inflammatory process, rather than H. pylori itself, was responsible for the induction of the
hypermethylation. However, in their subsequent gerbil study, neutrophilic inflammation
caused by treatment with ethanol or NaCl does not induce DNA methylation in these genes,
whereas chronic inflammation caused by H. pylori or H. felis infection leads to altered meth‐
ylation in candidate genes. This finding suggests that it is not the inflammation itself, but
rather specific types of inflammation, that are necessary for methylation induction[32].
3.3. Spread of de novo methylation of p16 CpG island from normal mucosae, gastritis, to
gastric carcinoma
It has been reported that p16 methylation is very stable in cultured cancer cell lines based on
its efficient recovery after the removal of a DNA methylation inhibitor treatment [21]. Tran‐
sient transfection of p16-specific artificial transcription factor can induce transcription of me‐
thylated p16 alleles in cancer cells, but cannot induce demethylation of its CpG islands [45].
In contrast, most p16 methylation in gastritis lesions is unstable and H. pylori-dependent [28,
30]. The mechanisms contributing to the difference of the stability of p16 methylation be‐
tween gastritis and cancer cells remains elusive. Characterization of the natural methylation
pattern of p16 CpG islands in human tissue samples with various pathological lesions may
elucidate the mechanisms accounting for the diverse stability of p16 methylation and could
potentially be used to develop a tumor-specific methylation biomarker assay. We demon‐
strated that in normal gastric tissues, the majority of the samples either did not show CpG
methylation or only contained sporadically methylated-CpG sites in the exon-1 coding-nu‐
cleosome region. In contrast, the gastritis and GC samples showed various degrees of meth‐
ylation in the same region. Extensive methylation in both the promoter and the exon-1
regions was observed in the majority of the GC specimens. We propose that a methylation
wave progressively extends from the p16 exon-1 coding- nucleosome to its promoter nucleo‐
some in vivo. (Fig. 3) The overall p16 methylation profiles constructed from a panel of clini‐
cal specimens may approximate the natural extension pattern of de novo methylation of p16
CpG islands in gastric carcinogenesis [46].
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Figure 3. Comparison of methylation status of p16 CpG island in gastric carcinomas, chromic gastritis, and normal
gastric mucosa [46]. A gray-graded representation of the average methylation density at individual CpG sites within
the p16 promoter and exon-1 region
4. DNA methylation as a clinical biomarker for risk assessment, and
anticancer drugs target
Epigenetic changes provide a potential explanation for how environmental factors can mod‐
ify the risk for common diseases among individuals. The growing interest in cancer epige‐
netics stems from the fact that epigenetic changes are implicated in virtually every step of
the development and progression of cancers. This is supported by the studies demonstrating
that epigenetic changes including DNA hypermethylation are an early event in carcinogene‐
sis. A distinguishing feature of epigenetic changes in comparison with genetic changes is
that epigenetic changes are reversible. Therefore, aberrant DNA methylation, histone acety‐
lation and methylation are attractive targets for cancer prevention and the epigenetic thera‐
py. There are some evidences that methylation-based tests could predict which individuals
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are at high risk for different types of cancers, so that screening tests and prophylactic treat‐
ment can be applied more effectively. A pharmacological modification of the epigenetic sta‐
tus may be a potent strategy for the prevention of gastric cancers, based on the fact that
methylation was a frequent event, particularly in H. pylori-infected patients. Perhaps meth‐
ylation in normal gastric mucosa either directly predisposes the tissue to cancer or is associ‐
ated with some other factors predisposing to cancer. In either case, methylation analysis of
normal tissue could help determine the risk of those individuals for future development of
the disease. It is reported that the genetic reduction of DNA methylation levels suppressed
the incidence, number and size of gastric tumors in gastric tumorigenesis [47].
Aberrant DNA methylation is more frequently present in gastric cancers than mutations
[48],  so we can take advantage of the frequent presence of aberrant methylation in can‐
cers  by using it  as  a  clue to  identify  tumor markers  for  cancer  screening purposes  and
carcinogenic risk assessment. One advantage of using aberrant DNA methylation as a bio‐
marker instead of mutations/expression is that it is possible to detect even a single aber‐
rantly methylated DNA molecule embedded in 1000 unmethylated DNA molecules [49].
The high sensitivity and specificity of measurements has particular application when it is
well recognized that stem cells in precancerous or cancer tissues should contribute to can‐
cer development, metastasis, recurrence, and formation of drug resistance. In contrast, us‐
ing regular gene expression assays, such as immunostaining, Western blot,  RT-PCR, and
Northern blot, detection of alterations of gene expression in limited number of stem cells
is very difficult. Additionally, DNA methylation can be remained in various samples stor‐
ed at wide-range conditions (fresh/frozen or paraffin- embedded tissue blocks, free DNA
in plasma,  detached cells  in  gastric  juice,  sputum, urine,  stool  samples,  and other  body
fluids).  For example,  we observed that  methylation of  p16,  the G1฀S conversion check‐
point gene in the cell cycle, is a powerful biomarker for prediction malignant transforma‐
tion  of  epithelial  dysplasia  [50,51].  Importantly,  we  further  developed  a  p16-specific
probe-based quantitative MethyLight assay for the development of p16 methylation diag‐
nosis  kit  [52].  Developments of  DNA methylation biomarkers (Septin9,  p16,  MGMT) for
cancer screening purposes, carcinogenic risk assessment, and prediction of chemotherapy
sensitivity are under clinical trials [3].
Currently, the greatest hopes are associated with clinical applications of several promising
epigenetic modification inhibitors target for anticancer therapy, which inhibits DNA methyl‐
ation and leads to the demethylation of the genome, thereby restoring expression of methy‐
lated genes. Such as DNMT inhibitor 5-aza-deoxycytosine and histone deacetylase inhibitors
vorinostat or romidepsin, have recently approved by FDA for patients with myelodysplasia
syndrome and cutaneous or peripheral T-cell lymphoma, respectively [3,53]. However, the
potential pleiotropic effects of such an intervention as a result of induced genome hypome‐
thylation (leading to, e.g., genome instability) need to be carefully considered. Therefore, the
basic challenge in designing potential anticancer drugs functioning at the DNA methylation
level is the specific recognition of molecular targets.
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5. Conclusion
In conclusion, aberrant CpG islands methylation occurs in the early stages of gastric carcino‐
genesis and tends to increase as the multistep process advances. It is highly plausible that H.
pylori infection and other environment exposure can lead to the adaptive responses of the
host cells to the chronic inflammation triggers the development of these epigenetic changes
in the non-cancerous stomach, which eventually lead to neoplastic transformation. The epi‐
genetic profile is highly dynamic and reversible, and varies among cells in the same organ‐
ism and, in the same cell, between various states, such as health versus disease, or in
response to environmental perturbations. Given the plasticity of epigenetic marks in re‐
sponse to cancer-related exposures, such epigenetic marks are attractive candidates for the
development of surrogate endpoints which could be used in dietary or lifestyle intervention.
In recent years, a lot has been learnt, but much remains to be learnt to combat gastric cancer,
one of the most frequent and lethal neoplasias worldwide. The study of epigenetic altera‐
tions offers great potential for the identification of biomarkers that can be used to detect and
diagnose cancer in its earliest stages, to accurately assess individual risk and as targets for
chemotherapeutic strategies.
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